Achieve Life Sciences, Inc. (ACHV) Stock Price & Analysis
Achieve Life Sciences, Inc. (ACHV) fell 1.13% to USD 6.1 as of July 25, 2026 at 06:44 UTC, according to Nexqual real-time market data.
ACHV last closed at USD 6.17; the session ranged USD 6.06–6.36 on volume of 906,515 shares. Market capitalization is $626.22M, with a 52-week range of USD 2.37–7.11 (NCM). Source: Nexqual, July 25, 2026 at 06:44 UTC.
Key Statistics (as of July 25, 2026 at 06:44 UTC)
| Price | USD 6.1 |
|---|---|
| Change | ▼ 1.13% (down) |
| Previous Close | USD 6.17 |
| Open | USD 6.24 |
| Day Range | USD 6.06 – 6.36 |
| 52-Week Range | USD 2.37 – 7.11 |
| Volume | 906,515 shares |
| Market Cap | $626.22M |
| Exchange | NCM |
Technical Analysis (ACHV)
Nexqual's technical model rates ACHV "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 06:44 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 52.07 (neutral) |
| vs SMA50 | Above (USD 5.63) |
| MACD | 0.18 (positive) |
Analyst Ratings (ACHV)
Wall Street analysts rate ACHV "Strong Buy" based on 10 analysts, with a mean price target of USD 13.8 (range USD 9–21), per Nexqual as of July 25, 2026 at 06:44 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 13.8 |
| High Target | USD 21 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (ACHV)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.15 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.19 vs est -0.3 ▲ beat |
| 2025-12-31 | USD -0.28 vs est -0.28 ▼ miss |
| 2025-09-30 | USD -0.28 vs est -0.26 ▼ miss |
| 2025-06-30 | USD -0.37 vs est -0.35 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:44 UTC.
Financials & Fundamentals (ACHV)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -496.15% |
| Debt / Equity | 140.03 |
| Current Ratio | 2.63 |
| Total Cash | $29.27M |
| Total Debt | $14.95M |
| Free Cash Flow | $-26.95M |
Source: Nexqual, July 25, 2026 at 06:44 UTC.
Financial Health Score (ACHV)
Nexqual rates Achieve Life Sciences, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:44 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $29M cash vs $15M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$45M |
| Efficiency | Critical — ROE -496%, ROA -108.4% |
Ownership (ACHV)
| Insider Ownership | +0.93% |
|---|---|
| Institutional Ownership | +64.23% |
| Shares Outstanding | 102.66M |
| Float | 87.47M |
| Short % of Float | +14.43% |
Source: Nexqual, July 25, 2026 at 06:44 UTC.
Leadership (ACHV)
Achieve Life Sciences, Inc. is led by Andrew D. Goldberg (age 43), CEO, President & Director, per Nexqual as of July 25, 2026 at 06:44 UTC.
| CEO, President & Director | Andrew D. Goldberg (age 43) |
|---|---|
| Chief Financial Officer | Mark K. Oki (age 56) |
| Senior Vice President of Commercial | Mark Zappia |
| Vice President of Strategic Communications & Stakeholder Relations | Nicole P. Jones |
Major Backers & Investors (ACHV)
Notable institutional backers of Achieve Life Sciences, Inc. include Franklin Resources, Inc., Propel Bio Management, LLC, Franklin Strategic Series-Franklin Biotechnology Discovery Fund, according to Nexqual as of July 25, 2026 at 06:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Franklin Resources, Inc. | 4.26% |
| Propel Bio Management, LLC | 3.69% |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 1.53% |
| Simplify Asset Management, Inc. | 1.4% |
| Simplify Exchange Traded Funds-Simplify Propel Opportunities ETF | 1.15% |
| Millennium Management | 1.05% |
| Marshall Wace LLP | 0.99% |
| LPL Financial LLC | 0.71% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.25% |
| State Street | 1.31% |
Source: Nexqual, July 25, 2026 at 06:44 UTC.
From Achieve Life Sciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
- The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
- It has license and supply agreements with Sopharma AD and University of Bristol.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AKTX | Akari Therapeutics Plc | USD 8.7 | ▼ 11.31% |
| XBIO | Xenetic Biosciences, Inc. | USD 2.64 | ▼ 1.12% |
| DARE | Dare Bioscience, Inc. | USD 1.28 | ▲ 4.92% |
| PRPO | Precipio, Inc. | USD 23.68 | ▲ 0.85% |
| ADIL | Adial Pharmaceuticals, Inc | USD 2.78 | ▲ 2.96% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:44 UTC. This page is informational and not investment advice.